Tc 99m arcitumomab

Drug Profile

Tc 99m arcitumomab

Alternative Names: CEA-Scan; ImmuRAID-CEA; ImmuRAID-CEA-Tc-99m; Tc-99m arcitumomab; Technetium Tc 99m arcitumomab

Latest Information Update: 12 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunomedics
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Colorectal cancer

Most Recent Events

  • 01 Jul 2003 Clinical data from a media release have been added to the adverse events section
  • 15 Jul 2002 Daiichi Pure Chemical obtains a non-exclusive licence to the CEA patents of Immunomedics
  • 13 Jun 2002 Tc 99m arcitumomab licensed to Teva-Tuteur in Latin Amerrica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top